{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T09:51:58Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 26.3, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09506-a149-72f3-bf2e-1817524335d9\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: fosphenytoin\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 re", "usd": 0.0, "recall": true }, "codex": { "seconds": 85.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09506-a14d-7dc2-a532-f00e3dc9585b\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: fosphenytoin\nRegistry id: vr.tr.fosphenytoin\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:56:41+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:31+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q5473363", "registryId": "vr.tr.fosphenytoin", "name": "fosphenytoin", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q5473363/", "model": { "registry_id": "vr.tr.fosphenytoin", "name": "fosphenytoin", "purpose": "Enable an agent to recognize fosphenytoin, assess the identity and condition of its material forms, and determine which analytical, handling, or medicinal-use constraints apply.", "definition": "Fosphenytoin is a water-soluble phosphate ester prodrug of phenytoin that is administered parenterally, generally as its sodium salt, and converted enzymatically to phenytoin for antiseizure activity.", "scope_statement": "This model owns vr.tr.fosphenytoin in PHY / PHY.MAT: the substance identity, distinctions among its chemical forms, material quality, conversion relationship to phenytoin, and evidence needed to interpret quantities and permitted uses.", "in_scope": [ "Fosphenytoin identity and explicit relationships to sodium salts, hydration states, and phenytoin", "Form-specific composition, purity, impurities, and analytical identification", "Physical state, solubility, stability, and storage-condition evidence", "Actual substance quantities and their distinction from phenytoin sodium equivalents", "Bioconversion and analytical interference relevant to recognizing the measured substance", "Substance hazards and links to applicable product labels, safety data, and regulatory records" ], "out_of_scope": [ "Finished injection products, their excipients, packaging, and commercial inventory", "Patient-specific seizure diagnosis, prescribing, dosing, and monitoring plans", "Phenytoin as an independently modeled substance", "Manufacturing processes, equipment, and facility qualification", "Administration devices and clinical procedures" ], "distinguishing_features": [ "Require a structure-specific identity test separating fosphenytoin from phenytoin; a shared therapeutic relationship does not establish chemical identity.", "Distinguish the fosphenytoin moiety from its sodium salt and any specified hydrate before matching identifiers or comparing molecular masses.", "Fosphenytoin converts to phenytoin after parenteral administration; the precursor and resulting active substance must remain separately identifiable. [DailyMed prescribing information, section 12.3](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0def32c-e693-43e5-9509-0cef9642441c)", "A quantity labeled mg PE expresses phenytoin sodium equivalents, not an unqualified mass of fosphenytoin. [DailyMed prescribing information, section 2.1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0def32c-e693-43e5-9509-0cef9642441c)", "An injection label identifies a preparation containing a specified fosphenytoin form; it does not establish that every property of that preparation is intrinsic to fosphenytoin." ], "characteristics": [ { "name": "Chemical form and structural identity", "kind": "category", "unit_or_values": "Structure identifier; counterion stoichiometry; hydration or solvation state; unresolved form", "why_it_matters": "Prevents merging distinct chemical forms or importing the wrong formula and molecular mass." }, { "name": "External identity mapping", "kind": "relation", "unit_or_values": "Verified CAS, PubChem, EC, or other identifier linked to its exact chemical form and source", "why_it_matters": "Supports traceable recognition without treating name matches as identity proof." }, { "name": "Fosphenytoin assay", "kind": "measurement", "unit_or_values": "% mass fraction or molar concentration, with chemical form, water correction, method, and uncertainty", "why_it_matters": "Determines how much verified substance a material contains." }, { "name": "Phenytoin and other related substances", "kind": "measurement", "unit_or_values": "% or mass concentration for each identified impurity, with detection limits", "why_it_matters": "Separates intact precursor from related substances and possible degradation products." }, { "name": "Quantity expression basis", "kind": "category", "unit_or_values": "mg of specified chemical form; mmol of fosphenytoin; mg PE; corresponding concentration units", "why_it_matters": "Prevents numerical comparisons or conversions across incompatible quantity bases." }, { "name": "Physical and solution state", "kind": "state", "unit_or_values": "Solid or dissolved; solvent; temperature; pH where applicable; observed precipitation", "why_it_matters": "Makes analytical and stability observations interpretable for the actual material." }, { "name": "Conditional physical constants", "kind": "measurement", "unit_or_values": "Solubility in g/L; thermal events in °C; pressure in kPa; exact form and method required", "why_it_matters": "Prevents product-specific or decomposition-associated measurements from becoming universal substance constants." }, { "name": "Conversion relationship", "kind": "relation", "unit_or_values": "Fosphenytoin precursor to phenytoin, with experimental matrix, conditions, and supporting evidence", "why_it_matters": "Connects material identity to transformation without conflating precursor and active metabolite." }, { "name": "Analytical selectivity", "kind": "category", "unit_or_values": "Separately resolves fosphenytoin and phenytoin; cross-reactive; unverified", "why_it_matters": "Determines whether a reported concentration identifies the intended analyte." }, { "name": "Use and hazard evidence", "kind": "relation", "unit_or_values": "Form-specific safety data, grade specification, jurisdiction, product-label link, and revision date", "why_it_matters": "Supports decisions about handling and intended use within the evidence's actual scope." } ], "affordances": [ "Resolve a supplier or laboratory record to fosphenytoin while retaining its exact salt and hydration state.", "Compare a material's identity, assay, and impurity results with a specified intended-use standard.", "Normalize quantities only when the chemical form and actual-mass or PE basis are explicit.", "Flag measurements that cannot distinguish fosphenytoin from phenytoin.", "Evaluate storage excursions against evidence for the same form and preparation.", "Route a proposed medicinal use to the applicable product label and clinical model, or flag missing prerequisites." ], "agent_conduct": { "may": [ "Describe fosphenytoin as an injectable prodrug of phenytoin used for seizures.", "Support clinical teams with dose and monitoring records they have authorised." ], "must_not": [ "Recommend, calculate or adjust a dose without a clinician's decision.", "Confuse doses expressed as phenytoin equivalents with the salt's own weight.", "Ignore low blood pressure or heart rhythm changes during infusion." ], "requires_human": [ "Starting, stopping or changing an infusion, especially in status epilepticus." ] }, "ethics": { "considerations": [ "Patients in prolonged seizures cannot speak for themselves; dosing errors cause serious harm." ], "affected_parties": [ "Patients with seizures", "Families", "Emergency and intensive care staff" ] }, "owners": { "steward": "The marketing authorisation holder; the treating clinician answers for each use.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "A solution for injection in vials; identity and strength are confirmed by label and pharmacy records." ], "failure_modes_and_hazards": [ "Rapid infusion can cause low blood pressure and dangerous heart rhythms.", "Dose unit confusion has led to serious overdoses.", "Itching and tingling during infusion." ], "what_it_is_for": [ "Fosphenytoin is encountered in hospital and emergency care as an injectable medicine used in the management of seizures.", "It is also used when temporary parenteral replacement of oral phenytoin is needed.", "Pharmaceutical laboratories examine its identity, purity and formulation quality." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology assigns fosphenytoin code N03AB05 within hydantoin derivative antiepileptics." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q5473363: fosphenytoin", "url": "https://www.wikidata.org/wiki/Q5473363", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Fosphenytoin", "url": "https://en.wikipedia.org/wiki/Fosphenytoin", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "fosphenytoin-identity", "name": "Fosphenytoin identity", "description": "Resolve the registered substance and the chemical forms represented by incoming records.", "rationale": "Fosphenytoin, its salts, phenytoin, and injection products require explicit boundaries.", "layers": [ { "id": "molecular-recognition", "name": "Molecular recognition", "description": "Establish identity through structure and selective analytical evidence.", "findings": [ { "id": "precursor-identity-test", "name": "Precursor identity test", "description": "Require evidence that identifies fosphenytoin separately from phenytoin and other related compounds.", "questions": [ { "text": "Which verified structure defines fosphenytoin for this registry entry?", "kind": "definition", "id": "precursor-identity-test-q01" }, { "text": "Which analytical result distinguishes the sample from phenytoin and structurally related impurities?", "kind": "measurement", "id": "precursor-identity-test-q02" } ] } ] }, { "id": "salt-and-record-boundaries", "name": "Salt and record boundaries", "description": "Attach identifiers and composition to the exact represented form.", "findings": [ { "id": "form-specific-identifiers", "name": "Form-specific identifiers", "description": "Retain counterion and hydration information when mapping names, identifiers, formulas, and molecular masses.", "questions": [ { "text": "Does this record represent the fosphenytoin moiety, a specified sodium salt, a hydrate, or a formulated solution?", "kind": "boundary", "id": "form-specific-identifiers-q01" }, { "text": "Which authoritative record verifies each identifier for that exact form?", "kind": "provenance", "id": "form-specific-identifiers-q02" } ] } ] } ] }, { "id": "fosphenytoin-material-quality", "name": "Fosphenytoin material quality", "description": "Assess intact substance content and the conditions under which a material remains suitable.", "rationale": "A correct name alone cannot establish purity, stability, or fitness for an intended use.", "layers": [ { "id": "assay-and-related-substances", "name": "Assay and related substances", "description": "Measure intact fosphenytoin and distinguish it from phenytoin and other components.", "findings": [ { "id": "intact-substance-content", "name": "Intact substance content", "description": "Record assay basis and separately quantified related substances rather than relying on an unspecified purity percentage.", "questions": [ { "text": "What is the fosphenytoin assay on the stated salt, hydration, and moisture basis?", "kind": "measurement", "id": "intact-substance-content-q01" }, { "text": "How much phenytoin and which other related substances are present, with what detection limits?", "kind": "measurement", "id": "intact-substance-content-q02" } ] } ] }, { "id": "phase-and-stability-conditions", "name": "Phase and stability conditions", "description": "Tie physical observations and stability limits to form, solvent, and environment.", "findings": [ { "id": "condition-dependent-suitability", "name": "Condition-dependent suitability", "description": "Require matching conditions before applying solubility, thermal, storage, or degradation evidence to a material.", "questions": [ { "text": "Which chemical form, solvent, pH, temperature, and pressure accompany the reported physical property?", "kind": "measurement", "id": "condition-dependent-suitability-q01" }, { "text": "What evidence supports accepting, retesting, or quarantining this material after its recorded storage history?", "kind": "action", "id": "condition-dependent-suitability-q02" } ] } ] } ] }, { "id": "fosphenytoin-quantity-and-conversion", "name": "Fosphenytoin quantity and conversion", "description": "Keep substance mass, equivalent quantities, and transformation observations distinct.", "rationale": "Equivalent labeling and conversion to a different analyte create specific opportunities for interpretation errors.", "layers": [ { "id": "mass-and-equivalent-bases", "name": "Mass and equivalent bases", "description": "Make every quantity's chemical and equivalence basis explicit.", "findings": [ { "id": "pe-aware-quantity-validation", "name": "PE-aware quantity validation", "description": "Require explicit mass or PE units, concentration denominators, and a sourced conversion rule before normalizing quantities.", "questions": [ { "text": "Does the value mean actual mass of a specified fosphenytoin form, amount in moles, or phenytoin sodium equivalents?", "kind": "definition", "id": "pe-aware-quantity-validation-q01" }, { "text": "Which verified conversion rule applies, and has an already PE-labeled value been protected from a second conversion?", "kind": "action", "id": "pe-aware-quantity-validation-q02" } ] } ] }, { "id": "conversion-and-analyte-resolution", "name": "Conversion and analyte resolution", "description": "Interpret observations in relation to conversion progress and assay selectivity.", "findings": [ { "id": "conversion-sensitive-measurement", "name": "Conversion-sensitive measurement", "description": "Some phenytoin immunoassays overestimate concentrations when fosphenytoin remains present; record method and sampling context. [DailyMed prescribing information, section 2.5](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0def32c-e693-43e5-9509-0cef9642441c)", "questions": [ { "text": "Which analyte and free or total fraction were measured, by which method, and at what sampling time?", "kind": "measurement", "id": "conversion-sensitive-measurement-q01" }, { "text": "Could assay cross-reactivity or conversion during sample handling explain the reported phenytoin result?", "kind": "boundary", "id": "conversion-sensitive-measurement-q02" } ] } ] } ] }, { "id": "fosphenytoin-use-constraints", "name": "Fosphenytoin use constraints", "description": "Connect material handling and medicinal-use decisions to applicable evidence.", "rationale": "Substance identity does not establish pharmaceutical suitability or authorize a clinical action.", "layers": [ { "id": "grade-and-handling-evidence", "name": "Grade and handling evidence", "description": "Establish what the material's specification and safety documentation actually support.", "findings": [ { "id": "form-specific-handling-basis", "name": "Form-specific handling basis", "description": "Keep chemical hazard classifications, exposure limits, and grade claims scoped to their source, form, and jurisdiction.", "questions": [ { "text": "Which current safety data and grade specification apply to this fosphenytoin material?", "kind": "provenance", "id": "form-specific-handling-basis-q01" }, { "text": "What handling or disposal action is supported, and which absent limits remain explicitly unknown?", "kind": "action", "id": "form-specific-handling-basis-q02" } ] } ] }, { "id": "medicinal-product-interface", "name": "Medicinal product interface", "description": "Transfer product-dependent and patient-dependent decisions to their owning models.", "findings": [ { "id": "clinical-constraint-handoff", "name": "Clinical constraint handoff", "description": "Injection labeling warns of severe hypotension and cardiac arrhythmias associated with rapid intravenous administration. Attach applicable label constraints through the product relationship. [DailyMed boxed warning](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0def32c-e693-43e5-9509-0cef9642441c)", "questions": [ { "text": "Which authorized product and current jurisdiction-specific label govern the proposed medicinal use?", "kind": "provenance", "id": "clinical-constraint-handoff-q01" }, { "text": "Which route, rate, contraindication, and monitoring checks must the clinical model resolve before administration?", "kind": "action", "id": "clinical-constraint-handoff-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This description is recalled knowledge; no sources were consulted.", "Verify registry identifiers, hydration state and physicochemical measurements against the exact substance form before assigning them.", "Verify jurisdiction-specific indications and safety requirements against current official prescribing information." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of fosphenytoin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "fosphenytoin", "note": "Names the drug substance; fosphenytoin sodium identifies its sodium salt." }, { "scheme": "Molecular formula", "value_or_pattern": "C16H15N2O6P", "note": "For fosphenytoin itself, excluding sodium counterions and water of hydration." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of fosphenytoin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Parenteral treatment of generalized convulsive status epilepticus.", "Short-term substitution for oral phenytoin when oral administration is unsuitable.", "Prevention and treatment of seizures associated with neurosurgery." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of fosphenytoin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of fosphenytoin", "typical_range": "362.27", "unit": "g/mol" }, { "quantity": "Clinical dose and concentration expression", "typical_range": "Expressed as phenytoin sodium equivalents (PE), which must be distinguished from fosphenytoin mass", "unit": "mg PE" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of fosphenytoin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Intravenous administration can cause severe hypotension and cardiac arrhythmias, particularly with excessive infusion rates.", "Confusing fosphenytoin mass with phenytoin sodium equivalents can cause dosing errors.", "Serious hypersensitivity reactions, including DRESS and severe cutaneous reactions, can occur.", "Conversion to phenytoin introduces clinically significant drug interactions and concentration-dependent neurological toxicity.", "Local tissue injury, including purple glove syndrome, can occur after peripheral intravenous administration." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of fosphenytoin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Approved indications, product availability and prescribing information vary by jurisdiction." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of fosphenytoin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Phenytoin", "difference": "Phenytoin is the active antiseizure compound; fosphenytoin requires enzymatic conversion to release it." }, { "name": "Fosphenytoin sodium", "difference": "The sodium salt is a distinct chemical form with counterions and potentially hydration water; its formula and molar mass differ from those of fosphenytoin." }, { "name": "Fosphenytoin sodium injection", "difference": "The injection is a formulated medicinal product with a specified concentration and excipients, rather than the chemical substance alone." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of fosphenytoin this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does vr.tr.fosphenytoin denote the parent chemical entity or an umbrella including sodium and hydrated forms, and does an existing catalogue model already cover it?", "Which CAS, PubChem, EC, formula, and molecular-mass records are verified for each represented chemical form?", "Which authoritative specifications establish assay, water content, phenytoin impurity, other related-substance limits, and grade suitability?", "Which form-specific sources establish solubility, thermal behavior, degradation pathways, and storage limits, including whether melting or boiling values are meaningful before decomposition?", "Which current safety data establish GHS classification, occupational exposure limits if any, and disposal requirements for bulk fosphenytoin forms in the relevant jurisdictions?" ], "statistics": { "bundles": 5, "layers": 9, "findings": 15, "questions": 23 } }